Compared to subsequent anti-tumor necrosis factor (anti-TNF) therapy, rituximab was associated with an increased likelihood of achieving low disease activity (LDA)/remission, modified American College of Rhematology (mACR) response, and physical function improvement. This according to a study of patients with active RA despite anti-TNF therapy. Researchers found that, compared to patients treated with a subsequent anti-TNF agent:

• Estimates for LDA/remission, mACR response, and modified Health Assessment Questionnaire (mHAQ) improvement were consistently better for rituximab.

• Odd ratios for likelihood of LDA/remission in rituximab was 1.35 in one population and 1.54 in another.

• Rituximab users were significantly more likely to achieve mACR and mHAQ improvement.

• Rates of new adverse event per 100 patient-years was similar between groups.

Citation: Harrold LR, Reed GW, Magner R, et al. Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry. Arthritis Res Ther. 1015 Sep 18;17(1):256. doi: 10/1186/s13075-015-0776-1.